I don't think our proposal is competing with Alpha Anstalt, which I expect is only going through a formality at the meeting Sunday. In fact I think it more likely we are a part of a larger plan with those parties that has been in development for awhile. Every conference we could hear this year, the questions were about ESS. I have lots of concerns, and I expect a more thorough explanation from the company to come soon along with other updates.

I welcome the unexpected news along with Dr. Urano's positive comments on MANF regenerative gene therapy, which I hope are a subtle indication from him that he's hearing good things on our end on ability for continued collaboration.